Feryan Ahmed

Glauconix Biosciences, Inc. is a company that specializes in developing ophthalmic ex-vivo dynamic 3D human tissue models for accelerating therapeutic innovation and drug discovery. The company is based in Albany, NY. The company's 3D tissue models can de-risk ophthalmic assets and expedite drug development, adding value to their clients and partners by expediting early identification and validation of effective compounds or biologics in the preclinical phase and those entering clinical trials. The company was founded in 2014 by Karen Torrejon, Feryan Ahmed. Kimberly R. Southern has been the CEO of the company since 2019.

Glauconix Biosciences, Inc. is a company that specializes in developing ophthalmic ex-vivo dynamic 3D human tissue models for accelerating therapeutic innovation and drug discovery. The company is based in Albany, NY. The company's 3D tissue models can de-risk ophthalmic assets and expedite drug development, adding value to their clients and partners by expediting early identification and validation of effective compounds or biologics in the preclinical phase and those entering clinical trials. The company was founded in 2014 by Karen Torrejon, Feryan Ahmed. Kimberly R. Southern has been the CEO of the company since 2019.

Glauconix Biosciences, Inc. is a company that specializes in developing ophthalmic ex-vivo dynamic 3D human tissue models for accelerating therapeutic innovation and drug discovery. The company is based in Albany, NY. The company's 3D tissue models can de-risk ophthalmic assets and expedite drug development, adding value to their clients and partners by expediting early identification and validation of effective compounds or biologics in the preclinical phase and those entering clinical trials. The company was founded in 2014 by Karen Torrejon, Feryan Ahmed. Kimberly R. Southern has been the CEO of the company since 2019.